Use of 21-gene recurrence score assay to individualize adjuvant chemotherapy recommendations in ER+/HER2− node positive breast cancer—A National Cancer Database study-Reference-Cited by-同舟云学术

Use of 21-gene recurrence score assay to individualize adjuvant chemotherapy recommendations in ER+/HER2− node positive breast cancer—A National Cancer Database study

Published:2017-10-19 Issue:1 Volume:3 Page:
ISSN:2374-4677
Container-title:npj Breast Cancer
language:en
Short-container-title:npj Breast Cancer

Author:

Peethambaram Prema P.,Hoskin Tanya L.,Day Courtney N.,Goetz Matthew P.,Habermann Elizabeth B.,Boughey Judy C.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Radiology Nuclear Medicine and imaging,Oncology

Link

http://www.nature.com/articles/s41523-017-0044-4.pdf

Reference43 articles.

1. Early Breast Cancer Trialists’ Collaborative Group. et al. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 386, 1341–1352 (2015).

2. Davies, C. et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381, 805–816 (2013).

3. Goss, P. E. et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med. 349, 1793–1802 (2003).

4. Gray, R. G. et al. aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J. Clin. Oncol. 31, 5 (2013).

5. Early Breast Cancer Trialists’ Collaborative Group. et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379, 432–444 (2012).

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of the 21-gene expression assay on treatment decisions and clinical outcomes in breast cancer with one to three positive lymph nodes;Frontiers in Endocrinology;2023-02-16

2. A rapid reduction in tumor size by cyclin-dependent kinase inhibition in hormone receptor-positive postpartum breast cancer: a case report of two patients and a review of the literature;Annals of Translational Medicine;2022-12

3. The Role of the 21-Gene Recurrence Score® Assay in Hormone Receptor-Positive, Node-Positive Breast Cancer: The Canadian Experience;Current Oncology;2022-03-16

4. Development and Validation of a New Multiparametric Random Survival Forest Predictive Model for Breast Cancer Recurrence with a Potential Benefit to Individual Outcomes;Cancer Management and Research;2022-03

5. Radiogenomic Signatures of Oncotype DX Recurrence Score Enable Prediction of Survival in Estrogen Receptor–Positive Breast Cancer: A Multicohort Study;Radiology;2021-11-30